RE:RE:New Press Release - Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerIt's a fairly small trial to gauge safety first. Then it moves up dosage and efficacy comes into play more. Winer has been a real advocate, having at least one of the long term stable patients in ovarian that he discussed on the call.
I doubt it warrants visits as the CRO gathers the data and they see it all real time. But I'm sure they will call or zoom in with investigators oretty constantly to monitor it. This is good news to know it is actually being tested now in its new regimen. Just have to see a few deep responses, most likely in the second part of this trial.